Federated Hermes Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 28.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 738,029 shares of the company’s stock after purchasing an additional 163,449 shares during the quarter. Federated Hermes Inc.’s holdings in Johnson & Johnson were worth $114,394,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. YHB Investment Advisors Inc. boosted its holdings in Johnson & Johnson by 1.5% in the 1st quarter. YHB Investment Advisors Inc. now owns 65,999 shares of the company’s stock valued at $10,230,000 after purchasing an additional 994 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Johnson & Johnson by 4.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 970,695 shares of the company’s stock valued at $150,458,000 after buying an additional 41,055 shares in the last quarter. Harvey Investment Co. LLC grew its holdings in Johnson & Johnson by 1.6% during the first quarter. Harvey Investment Co. LLC now owns 227,970 shares of the company’s stock worth $35,335,000 after acquiring an additional 3,554 shares during the period. Truepoint Inc. raised its position in Johnson & Johnson by 30.8% in the first quarter. Truepoint Inc. now owns 3,521 shares of the company’s stock worth $546,000 after acquiring an additional 829 shares in the last quarter. Finally, Smart Money Group LLC boosted its position in shares of Johnson & Johnson by 2.6% during the 1st quarter. Smart Money Group LLC now owns 2,604 shares of the company’s stock worth $426,000 after purchasing an additional 65 shares in the last quarter. 67.57% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 0.3 %
Shares of Johnson & Johnson stock opened at $172.92 on Wednesday. The firm has a market cap of $449.41 billion, a PE ratio of 35.00, a P/E/G ratio of 2.92 and a beta of 0.54. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The business’s fifty day moving average is $165.50 and its two-hundred day moving average is $161.20.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.75%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. Barclays increased their target price on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a report on Monday, July 24th. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Finally, Credit Suisse Group raised their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $171.80.
Get Our Latest Analysis on JNJ
Insider Transactions at Johnson & Johnson
In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 in the last ninety days. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- On Holding Slips Into A More Comfortable Price PointÂ
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Growing Cannabis Stocks Ready To Bloom
- Investing in Blue-Chip Stocks
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
